Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "Alembic-Pharma"

109 News Found

Alembic Pharmaceuticals receives USFDA final approval for Pirfenidone tablets
Drug Approval | May 24, 2022

Alembic Pharmaceuticals receives USFDA final approval for Pirfenidone tablets

The tablets have an estimated market size of US $ 548 million for twelve months ending December 2021 according to IQVIA


Alembic Pharmaceuticals receives USFDA  approval for Arformoterol Tartrate
Drug Approval | May 11, 2022

Alembic Pharmaceuticals receives USFDA approval for Arformoterol Tartrate

This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies


Alembic Pharmaceuticals receives USFDA tentative approval for heart failure drug
Drug Approval | April 20, 2022

Alembic Pharmaceuticals receives USFDA tentative approval for heart failure drug

Ivabradine Tablets, 5 mg and 7.5 mg have an estimated market size of US $ 102 million for twelve months ending December 2021 according to IQVIA


Alembic Pharma acquires 100% stake in Aleor Dermaceuticals
News | March 29, 2022

Alembic Pharma acquires 100% stake in Aleor Dermaceuticals

The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic


Alembic Pharmaceuticals receives USFDA approval for Lacosamide tablets
Drug Approval | March 21, 2022

Alembic Pharmaceuticals receives USFDA approval for Lacosamide tablets

The tablets are indicated for the treatment of partial-onset seizures in patients 4 years of age and older


Alembic Pharma PAT at Rs 169.29 cr. in Q2FY22
News | November 11, 2021

Alembic Pharma PAT at Rs 169.29 cr. in Q2FY22

The Board of Directors of Alembic Pharmaceuticals have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021.


Alembic Pharmaceuticals Q1FY22 net slides to Rs. 164.52 Cr
News | July 27, 2021

Alembic Pharmaceuticals Q1FY22 net slides to Rs. 164.52 Cr

The US business faced price erosion due to increased competition.


Alembic announces USFDA Final Approval for Carbamazepine Tablets USP, 200 mg
Drug Approval | April 17, 2025

Alembic announces USFDA Final Approval for Carbamazepine Tablets USP, 200 mg

Carbamazepine Tablets USP, 200 mg have an estimated market size of US$ 32 million for twelve months ending December 2024 according to IQVIA


Alembic announces USFDA final approval for Pantoprazole Sodium for Injection, 40 mg/vial
Drug Approval | April 03, 2025

Alembic announces USFDA final approval for Pantoprazole Sodium for Injection, 40 mg/vial

Pantoprazole Sodium for Injection, 40 mg/vial (Single-Dose Vial) have an estimated market size of US$ 48 million for twelve months ending December 2024 according to IQVIA


Budget 2025: Industry welcomes customs duty exemptions on 36 life-saving drugs and medicines
Policy | February 01, 2025

Budget 2025: Industry welcomes customs duty exemptions on 36 life-saving drugs and medicines

The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25